Telcardis Tablet 40mg10 tablets
Telcardis 40mg tablet: White, shieldshaped tablet; each tablet contains Telmisartan USP 40mg.
Telcardis 80mg tablet: White, diamondshaped tablet; each tablet contains Telmisartan USP 80mg.
Telmisartan is a nonpeptideangiotensin II receptor antagonist which is used in the treatment of hypertension.
Telcardis is an angiotensin II receptor blocker (ARB) indicated for treatment of hypertension and Cardiovascular (CV) risk
reduction in patients who are indicated for ACE inhibitors.
Dosage & Administration
In case of hypertension usually 40mg once daily. Increased if necessary after at least 4 weeks to maximum 80mg once daily.
Prevention of cardiovascular events 80mg once daily.
Most people tolerate telmisartan well.Side effects are usually minor and either require no treatment or can easily be treated by
physician. The most common telmisartan side effects include-Upper respiratory infection such as the common cold or flu up to 7
percent of people, Back pain up to 3 percent of people, Diarrhea up to 3 percent of people, Inflammation of the sinuses up to 3
percent of people.
Telmisartan is contraindicated in conditions like Pregnancy, Adjunct in treatment of opioid dependence, Dry or painful cough.
Telmisartan is also contraindicated in patients with known hypersensitivity to telmisartan.
Following oral administration, peak concentrations (Cmax) of telmisartan are reached in 0.5 to 1 hour after dosing. Food slightly
reduces the bioavailability of telmisartan, with a reduction in the area under the plasma concentration-time curve (AUC) of about
6% with the 40mg tablet and about 20% after a 160mg dose. The absolute bioavailability of telmisartan is dose dependent. At 40mg
and 160mg the bioavailability was 42% and 58% respectively.
When certain medicines are taken together, there is a possibility of developing drug interactions. With Telmisartan, drugs such as
potassium supplements or potassium-sparing diuretics may cause an interaction. When Telmisartan was co-administered with digoxin,
median increases in digoxin peak plasma concentration (49%) and in through concentration (20%) where observed. Therefore, monitor
digoxin levels when initiating, adjusting and discontinuing Telmisartan for the purpose of keeping the digoxin level within the
therapeutic range. NSAID use may lead to increase risk of renal impairment and loss of antihypertensive effect. Monitor renal
function periodically in patients receiving Telmisartan and NSAID therapy.
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal
function and increases fetal and neonatal morbidity and death. Telmisartan may potentially cause extreme low blood pressure or
a decrease in kidney function. Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal
impairment, heart failure, on renal replacement therapy or on potassium supplements, potassium-sparing diuretics, potassium
containing salt substitutes or other drugs that increase potassium levels.
Pregnancy and Lactation
Telmisartan has been assigned to pregnancy categories C (use during first trimester) by the FDA. When pregnancy is detected
or expected, Telmisartan should be discontinued as soon as possible. The use of drugs that act directly on the RAA system during
the second and third trimesters has been associated with fetal and neonatal injury, including hypotension, neonatal skull
hypoplasia, anuria, reversible or irreversible renal failure and death. There are no data on the excretion of Telmisartan into
human milk, due to the potential for serious adverse effects in the nursing infant, a decision should be made to discontinue
nursing or discontinue the drug.
Store in a cool and dry place, protected from light. Keep out of children’s reach .
Telcardis 40mg tablet: Each pack contains 14 tablets. Telcardis 80mg tablet: Each pack contains 14 tablets.